Dapagliflozin protects against dilated cardiomyopathy progression by targeting NLRP3 inflammasome activation

Dilated cardiomyopathy (DCM) is the major cause of heart failure and has a poor prognosis. The accumulating evidence points to an essential role of the inflammatory component in the process of DCM. Inhibitors of sodium-glucose cotransporter 2 (SGLT2) are widely used to treat heart failure patients d...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Jiaxin, Xu, Jiamin, Tan, Xi, Li, Dong, Yao, Dejiang, Xu, Biao, Lei, Yuhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244283/
https://www.ncbi.nlm.nih.gov/pubmed/36749400
http://dx.doi.org/10.1007/s00210-023-02409-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244283/
https://www.ncbi.nlm.nih.gov/pubmed/36749400
http://dx.doi.org/10.1007/s00210-023-02409-5

Ejemplares similares